Kore Potash Plc (KP2)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 0.065 |
|---|---|
| 52-week range | 0.046 – 0.074 |
| Return, 1 month / 3 months | −7.1% / +10.2% |
| Return, 1 year / 3 years | −1.5% / +400.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 30 |
| Volatility (1 year) | 44.6% |
| Worst drawdown (1 year) | -29.4% |
| Average daily value traded | 0.01M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kore Potash is a mineral development company working to build a potash mine in the Republic of the Congo. Its projects centre on the Sintoukola area, where it is developing the Kola and DX deposits to produce muriate of potash, a fertiliser ingredient used by agricultural customers around the world. The company is based in the United Kingdom and its ordinary stock trades on public markets, including the Australian Securities Exchange.
Kore Potash Plc trades under the code KP2 on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kore Potash Plc (KP2) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.065 on 23 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 355 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.5% and over the last three months it rose 10.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.5% | ||
| From 52-week high | -11.0% | ||
| Momentum | 79 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.2% | ||
| 6-month return | 8.3% | ||
| 12-month return, skipping the last month | 6.1% | ||
| Stability (higher is calmer) | 80 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.4% | ||
| Liquidity | 18 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M AUD | ||
| Zero-volume days | 33.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.4% |
|---|---|
| 1 month | −7.1% |
| 3 months | +10.2% |
| 6 months | +8.3% |
| 1 year | −1.5% |
| 3 years | +400.0% |
| 5 years | +170.8% |
Signals
| 50-day / 200-day average | 0.066 / 0.062 |
|---|---|
| Golden / death cross (60 days) | Golden, 41 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.001 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.